Overall survival (OS) of EGFR mutation-positive non-small cell lung cancer (NSCLC) patients: Real-world treatment patterns of 1,660 Japanese patients (pts).

被引：0
|
作者：
Kazushi, Yoshida
Inoue, Akira
Sugawara, Shunichi
Murakami, Shuji
Saka, Hideo
Morita, Satoshi
Kim, Young Hak
Imamura, Fumio
Takeda, Koji
Nakagawa, Kazuhiko
Takeda, Masayuki
Atagi, Shinji
Hasegawa, Yoshikazu
Yamamoto, Nobuyuki
Katakami, Nobuyuki
Yoshioka, Hiroshige
Iwamoto, Yasuo
Okamoto, Isamu
Seto, Takashi
Ohe, Yuichiro
机构：
[1] Natl Canc Ctr, Tokyo, Japan
[2] Tohoku Univ Hosp, Sendai, Miyagi, Japan
[3] Sendai Kousei Hosp, Sendai, Miyagi, Japan
[4] Kanagawa Canc Ctr, Dept Thorac Oncol, Yokohama, Kanagawa, Japan
[5] Nagoya Med Ctr, Nagoya, Aichi, Japan
[6] Kyoto Univ, Grad Sch Med, Dept Biomed Stat & Bioinformat, Kyoto, Japan
[7] Kyoto Univ Hosp, Kyoto, Japan
[8] Osaka Med Ctr Canc & Cardiovasc Dis, Dept Pulm Oncol, Osaka, Japan
[9] Osaka City Gen Hosp, Dept Med Oncol, Osaka, Japan
[10] Kinki Univ, Sch Med, Osaka, Japan
[11] Kinki Univ, Fac Med, Dept Med Oncol, Osaka, Japan
[12] Kinki Chuo Chest Med Ctr, Osaka, Japan
[13] Kinki Univ, Sakai Hosp, Sch Med, Sakai, Osaka, Japan
[14] Wakayama Med Univ, Dept Internal Med 3, Wakayama, Japan
[15] Inst Biomed Res & Innovat, Div Integrated Oncol, Kobe, Hyogo, Japan
[16] Kurashiki Cent Hosp, Kurashiki, Okayama, Japan
[17] Hiroshima City Hosp, Dept Med Oncol, Hiroshima, Japan
[18] Kyushu Univ Hosp, Fukuoka, Japan
[19] Natl Kyushu Canc Ctr, Fukuoka, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.e20503
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e20503
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Influence of dose adjustment on afatinib safety and efficacy in patients (pts) with advanced EGFR mutation-positive (EGFRm plus ) non-small cell lung cancer (NSCLC).
    Yang, James Chih-Hsin
    Ahn, Myung-Ju
    Dickgreber, Nicolas J.
    Halmos, Balazs
    Hirsh, Vera
    Hochmair, Maximilian J.
    Levy, Benjamin Philip
    De Marinis, Filippo
    Mok, Tony
    O'Byrne, Kenneth
    Okamoto, Isamu
    Schuler, Martin H.
    Sebastian, Martin
    Shah, Riyaz N. H.
    Tan, Eng-Huat
    Yamamoto, Nobuyuki
    Marten, Angela
    Massey, Dan
    Wind, Sven
    Carbone, David Paul
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [32] Improving survival in EGFR mutation-positive non-small cell lung cancer: Tokushukai REAl world Data project (TREAD 01)
    Uryu, Kiyoaki
    Yosinori, Imamura
    Rai, Shimoyama
    Takahiro, Mase
    Yoshiaki, Fujimura
    Maki, Hayashi
    Megu, Ohtaki
    Keiko, Otani
    Nobuaki, Shinozaki
    Hironobu, Minami
    ANNALS OF ONCOLOGY, 2022, 33 : S522 - S522
  • [33] Real-world management of patients with epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer in the USA
    Li, Yulin
    Appius, Anita
    Pattipaka, Thirupathi
    Feyereislova, Andrea
    Cassidy, Adrian
    Ganti, Apar Kishor
    PLOS ONE, 2019, 14 (01):
  • [34] Patterns of progression on first line osimertinib in patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC): A Swiss cohort study
    Schuler, A.
    Huser, J.
    Schmid, S.
    Schar, S.
    Scherz, A.
    Gautschi, O.
    Mauti, L.
    von Briel, T.
    Waibel, C.
    Pankovics, J.
    Mark, M. T.
    Rothschild, S. I.
    Addeo, A.
    Janthur, W. D.
    Siano, M.
    Boos, L.
    Britschgi, C.
    Fruh, M.
    LUNG CANCER, 2024, 187
  • [35] REAL-WORLD UTILIZATION OF BRIGATINIB IN PATIENTS WITH NON-SMALL CELL LUNG CANCER (NSCLC)
    Lin, H. M.
    Pan, X.
    Hou, P.
    Huang, H.
    Baumann, P.
    Jahanzeb, M.
    VALUE IN HEALTH, 2019, 22 : S115 - S115
  • [36] Long-term survival and treatment (tx) patterns after first-line (1L) osimertinib in patients (pts) with epidermal growth factor receptor (EGFR) mutation-positive (m) advanced non-small cell lung cancer (NSCLC): Japanese cohort of a global real-world (rw) observational study
    Fujimoto, D.
    Takiguchi, Y.
    Matsumoto, S.
    Yamamoto, N.
    Saito, G.
    Nishimura, Y.
    Sugiyama, S.
    Oku, A.
    Karia, P.
    Antunes, L.
    Chapaneri, J.
    Salomonsen, R. J-B.
    Martin, E.
    Okhuoya, P.
    Muto, M.
    ANNALS OF ONCOLOGY, 2023, 34 : S1657 - S1658
  • [37] The Plasma Concentration of Epidermal Growth Factor Receptor (EGFR) and Overall Survival (OS) in Non-Small Cell Lung Cancer (NSCLC) Patients
    Ye, P.
    Zhao, J.
    Maihle, N.
    Wang, S. L.
    Jin, J. Y.
    Kong, F. M. P.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2015, 93 (03): : E445 - E445
  • [38] First-line treatment and overall survival in EGFR mutation-positive advanced non-small cell lung cancer: a national cohort study
    Huang, L. -y.
    Chang, H. -p.
    Chang, R. -y.
    Tai, H. -y.
    Huang, Y. -w.
    Lee, P. -c.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2022, 26 (20) : 7632 - 7640
  • [39] Overall survival comparison in patients with and without brain metastases treated with osimertinib for metastatic EGFR mutation positive non-small cell lung cancer (NSCLC).
    Mata, Danilo Giffoni de Mello Morais
    Romero, Maria Luisa
    Gonzalez, Carlos Amir Carmona
    Thawer, Alia
    Doherty, Mark
    Menjak, Ines B.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [40] ADVERSE EVENTS COSTS ASSOCIATED WITH ERLOTINIB OR AFATINIB IN NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS WITH EGFR MUTATION-POSITIVE TUMOURS
    Isla, D.
    De Castro, J.
    Juan Vidal, O.
    Grau, S.
    Orofino, J.
    Gordo, R.
    Rubio-Terres, C.
    Rubio-Rodriguez, D.
    VALUE IN HEALTH, 2015, 18 (07) : A429 - A429
12345